Gene: UBL7
Official Full Name: ubiquitin like 7provided by HGNC
Gene Summary: Enables molecular adaptor activity. Predicted to be involved in ubiquitin-dependent protein catabolic process. Is active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO24359 | UBL7 Knockout cell line (HeLa) | Human | UBL7 | 1:3~1:6 | Negative | Online Inquiry |
KO24360 | UBL7 Knockout cell line (HCT 116) | Human | UBL7 | 1:2~1:4 | Negative | Online Inquiry |
KO24361 | UBL7 Knockout cell line (HEK293) | Human | UBL7 | 1:3~1:6 | Negative | Online Inquiry |
KO24362 | UBL7 Knockout cell line (A549) | Human | UBL7 | 1:3~1:4 | Negative | Online Inquiry |
UBL7 Gene Knockout Cell Lines are engineered cellular systems designed to effectively disrupt the expression of the UBL7 gene, a gene implicated in various cellular processes including protein ubiquitination and cellular stress responses. These cell lines are generated through advanced gene-editing techniques, such as CRISPR/Cas9, allowing for precise knockout of the UBL7 gene. The resulting cell lines serve as invaluable tools for researchers exploring the gene's role in biological functions and its impact on health and disease.
The primary mechanism of action of UBL7 Gene Knockout Cell Lines involves the complete abrogation of UBL7 expression, leading to altered cellular behaviors that can be meticulously studied. Researchers can utilize these knockout models to investigate the gene's involvement in critical pathways, such as the regulation of the cell cycle, apoptosis, and stress responses, thereby enhancing our understanding of how dysregulation may contribute to diseases like cancer and neurodegenerative disorders.
In scientific and clinical research settings, these cell lines offer unique insights that are crucial for translational research. By allowing for the observation of phenotypic changes following UBL7 knockout, researchers can identify potential therapeutic targets and innovative treatment strategies. Furthermore, UBL7 Gene Knockout Cell Lines stand out compared to traditional knockdown approaches—such as RNA interference—by providing stable and heritable alterations in the genetic material, allowing for more consistent experimental results over extended studies.
For researchers and clinicians, the value of UBL7 Gene Knockout Cell Lines is accentuated by their ability to bridge basic science with clinical applications, ensuring that findings can be translated into potential therapies. The reliability and robustness of these models position them as essential components in the toolbox of molecular and cellular biologists.
Our company, known for its commitment to delivering cutting-edge biological products, leverages years of expertise in gene editing technologies to provide researchers with reliable and innovative tools. The UBL7 Gene Knockout Cell Lines are a testament to our dedication to advancing scientific discovery and improving outcomes in health research.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.